01—Abstract
Summary
Summary of the 8-K/A filed January 24, 2025. Cited figures are marked; the original filing is the authoritative source.
Colgate-Palmolive's 8-K/A (Amendment No. 1) is a technical filing: it adds an Item 2.02 tag to the October 25, 2024 8-K so EDGAR reflects the earnings release correctly.
No substantive content from the original report changed. The attached Exhibit 99.1 (Q3 2024 results) is the substantive material for investors. Q3 2024 net sales rose 2.4% to $5,033 milliona, organic sales rose 6.8%, and GAAP diluted EPS rose 5% to $0.90 (Base Business EPS of $0.91, up 6%).
Gross margin expanded 260 basis points to 61.1%, and operating profit grew 4% to $1,065 millionb. Management raised full-year 2024 guidance for net sales growth (3% to 5%), organic sales growth (7% to 8%), and Base Business EPS growth (10% to 11%). Nine-month operating cash flow was $2,838 million, and free cash flow before dividends was $2,461 million.
The filing also includes Item 8.01, which discloses a segment realignment effective July 1, 2024. Skin health businesses formerly reported in Europe now sit within North America. Management recast historical geographic segment data (Exhibit 99.2) to reflect the change.
The company states this has no effect on consolidated results, financial position, or cash flows, and that the recast does not restate previously issued financials. Investors comparing regional performance should use the recast figures, since North America and Europe growth rates are not comparable to pre-July 2024 reporting. Europe's reported Q3 operating profit growth of 10%c and North America's decline of 9% both reflect this realignment, so the regional comparison is partly a reporting artifact.
The quarter's main watch items are the sharp divergence across divisions and regions and the sizable FX headwind. Hill's Pet Nutrition operating profit rose 28%d with margin up 390 basis points.
Latin America organic sales grew 14.2%, but reported sales fell 3.2% due to a 17.4% foreign exchange drag. Advertising spend rose 16% to $694 million in the quarter, and management expects continued strong investment through year-end.
02—Key points
Key Highlights
- Q3 2024 net sales grew 2.4% to $5,033 million, with organic sales up 6.8% on top of 8.8% growth a year earlier, driven by a mix of volume (+3.7%) and pricing (+3.1%), partly offset by FX (-4.4%).
- GAAP diluted EPS increased 5% to $0.90; Base Business (non-GAAP) EPS rose 6% to $0.91, marking the sixth consecutive quarter of gross margin expansion alongside growth in operating profit, net income, and EPS.
- Gross profit margin expanded 260 basis points to 61.1% (Base Business 61.3%, up 270 bps), while operating margin rose 30 bps to 21.2%.
- Full-year 2024 guidance was raised: net sales growth now 3% to 5% (from 2% to 5%), organic sales growth 7% to 8% (from 6% to 8%), and Base Business EPS growth 10% to 11% (from 8% to 11%), with a mid-single-digit FX headwind to sales.
- Hill's (Pet Nutrition) was the standout division, with Q3 net sales up 6.3% and operating profit up 28% to $258 million, with margin expanding 390 bps to 22.9%.
- Management realigned skin health reporting from Europe to North America effective July 1, 2024; historical segment data was recast with no impact on consolidated results, and prior-period regional comparisons should use the recast figures.
- Nine-month operating cash flow was $2,838 million (vs. $2,609 million prior year), with free cash flow before dividends of $2,461 million; share repurchases totaled $1,284 million and dividends $1,275 million.
03—Questions
Frequently Asked Questions
Why did Colgate file an amended 8-K for an October 2024 earnings release?
The amendment was filed solely to ensure an additional Item 2.02 tag is reflected in EDGAR for the original October 25, 2024 8-K. No other changes were made to the report or its exhibits, including the earnings release (Exhibit 99.1) and recast segment data (Exhibit 99.2).
Did the skin health reclassification change Colgate's consolidated financial results?
No. Management states the realignment has no impact on consolidated results of operations, financial position, or cash flows. It moves skin health businesses from the Europe segment into North America, so segment-level figures for those regions change, but company totals do not.
How strong was Colgate's Q3 2024 performance relative to its underlying growth?
Performance was solid. Organic sales grew 6.8% and Base Business EPS rose 6%, with gross margin expanding 270 bps on a Base Business basis. Reported net sales growth of 2.4% was held back by a 4.4% foreign exchange headwind, which was largest in Latin America (-17.4%).
What drove the guidance raise, and how much room is there for upside or risk?
Management raised its net sales, organic sales, and Base Business EPS outlook, citing strong first-half results and continued confidence in its strategy. The guidance is based on current spot rates, so further currency moves could affect the reported net sales outcome, which still carries a mid-single-digit FX drag.
Where are the biggest regional and divisional divergences investors should watch?
Latin America posted 14.2% organic growth but reported a 3.2% sales decline due to currency. North America's operating profit fell 9% to $206 million, with margin down 170 bps, while Hill's profit rose 28%. Because of the segment recast, comparisons of North America and Europe against prior periods should use the recast Exhibit 99.2 data.
04—Continue